Jump to contents

Researcher Information

last modified:2024/03/29

Professor KATO Yukio

Mail Laboratory Website

Faculty, Affiliation

Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences

College and School Educational Field

Division of Health Sciences, Graduate School of Phamaceutical Science
Division of Pharmacy, Graduate School of Medical Science
School of Pharmaceutical Sciences, College of Medical, Pharmaceutical and Health Sciences
School of Pharmacy, College of Medical, Pharmaceutical and Health Sciences

Laboratory

Department of Molecular Pharmacotherapeutics TEL:076-234-4465 FAX:076-234-4465

Academic Background

【Academic background(Doctoral/Master's Degree)】
The University of Tokyo Doctor Graduate School of Pharmaceutical Sciences 199307 Unfinished course
【Academic background(Bachelor's Degree)】
The University of Tokyo 199003
【Degree】
Ph.D.

Career

Kanazawa University Faculty of Pharmacy Professor(2008/09/01-)
Kanazawa University Faculty of Pharmaceutical Sciences Assistant Professor(2002/06/01-2008/08/31)
National Institutes of Health National Institute of Child Health & Visiting Fellow(2001/04/01-2002/05/31)
University of Tokyo Faculty of Pharmaceutical Sciences Research Associate(1993/08/01-2002/05/31)

Year & Month of Birth

1967/09

Academic Society


Japanese Society for the Study of Xenobiotics

The Japanese Pharmacological Society

International Society for the Study of Xenobiotics

Award

○Banyu Young Scientist Award for Pharmaceutics(2000/04/01)
○New Investigator Award(2006/05/26)
○New Investigator Award(2006/11/29)
○New Investigator Award(2008/05/21)

Specialities

Pharmacokinetics、Pharmacotherapeutics、protein-protein interaction

Speciality Keywords

Physiologically-based pharmacokinetics and drug metabolism,Pharmacotherapeutics,Drug transporters,neurogenesis,Cytokines

Research Themes

Transporter-mediated disposition and delivery of therapeutic agents

Regulation mechanisms of localization and function of xenobiotic transporters

Pharmacokinetics and delivery of biologically active proteins and macromolecules

Books

  •  Peptide and protein delivery targeted to receptor-mediated endocytosis. Crit 14 3 173-219 1997
  •  Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. 42 (suppl) S44-S49 1997
  •  Sugiura T, Kato Y, Tsuji A.  Role of SLC xenobiotic transporters and their regulatory mechanisms PDZ proteins in drug delivery and disposition.  116 2 238-246 2006/11
  •  Kato Y, Watanabe C, Tsuji A.  Regulation of drug transporters by PDZ adaptor proteins and nuclear receptors.  27 5 487-500 2006/04
  •  Kato Y Xenobiotic transporter-adaptor network.  22 6 401-408 2007/12

show all

  •  Sugiura T, Shimizu T, Kijima A, Minakata S, Kato Y. PDZ adaptors: Their regulation of epithelial transporters and involvement in human diseases. 100 9 3620-3635 2011/07

Papers

  •  Existence of two pathways for the endocytosis of epidermal growth factor by rat liver: Phenylarsine oxide-sensitive and -insensitive pathways. Kato Y, Sato H, Ichikawa M, Suzuki H, Sawada Y, Hanano M, Fuwa T, Sugiyama Y.  Proc Natl Acad Sci USA 89 18 8507-8511 1992
  •  Importance of the liver in plasma clearance of hepatocyte growth factors in rats.  Liu KX, Kato Y, Narukawa M, Kim DC, Hanano M, Higuchi O, Nakamura T, Sugiyama Y.  Am J Physiol 263 (5 Pt 1) G642-G649 1992
  •  Binding, internalization, degradation, and mitogenic effect of epidermal growth factor in cultured rat hepatocytes.  Kato Y, Sugiyama Y.  STP PHARMA SCIENCES 3 1 75-82 1993
  •  Decrease in the hepatic clearance of hepatocyte growth factor in carbon tetrachloride-intoxicated rats.  Liu KX, Kato Y, Yamazaki M, Higuchi O, Nakamura T, Sugiyama Y.  HEPATOLOGY 17 4 651-660 1993
  •  Effect of perfusate pH on the influx of 5-5'-dimethyl-oxazolidine-2,4-dione and dissociation of epidermal growth factor from the cell-surface receptor: the existence of the proton diffusion barrier in the Disse space.  Ichikawa M, Kato Y, Miyauchi S, Sawada Y, Iga T, Fuwa T, Hanano M, Sugiyama Y.  JOURNAL OF HEPATOLOGY 20 2 190-200 1994

show all

  •  Heparin-hepatocyte growth factor complex with low plasma clearance and retained hepatocyte proliferating activity.  Kato Y, Liu KX, Nakamura T, Sugiyama Y.  HEPATOLOGY 20 2 417-424 1994
  •  Change in hepatic handling of hepatocyte growth factor during liver regeneration in rats.  Liu KX, Kato Y, Terasaki T, Nakamura T, Sugiyama Y.  AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY 269 (5 Pt 1) G745-G753 1995
  •  Contribution of parenchymal and non-parenchymal liver cells to the clearance of hepatocyte growth factor from the circulation in rats.  Liu KX, Kato Y, Terasaki T, Aoki S, Okumura K, Nakamura T, Sugiyama Y.  PHARMACEUTICAL RESEARCH 12 11 1737-1740 1995
  •  The endothelin receptor is a major determinant for the nonlinear tissue distribution of the endothelin antagonist BQ-123.  Shin HC, Kato Y, Shitara Y, Yamada T, Nakamura T, Hisaka A, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 278 2 607-613 1996
  •  Cell density-dependent mitogenic effect and -independent cellular handling of epidermal growth factor in primary cultured rat hepatocytes.  Hamada T, Kato Y, Terasaki T, Sugiyama Y.  JOURNAL OF HEPATOLOGY 26 2 353-360 1997
  •  Kinetic analysis of transcytosis of epidermal growth factor in Madin-Darby Canine Kidney epithelial cells. Kozu A, Kato Y, Shitara Y, Hanano M, Sugiyama Y.  PHARMACEUTICAL RESEARCH 14 9 1228-1235 1997
  •  Existence of two nonlinear elimination mechanisms for hepatocyte growth factor in rats. Liu KX, Kato Y, Kato M, Kaku TI, Nakamura T, Sugiyama Y.  AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM 273 5Pt1 E891-E897 1997
  •  Immunological response to repeated administration of recombinant human erythropoietin in rats: biphasic effect on its pharmacokinetics.  Kato M, Miura K, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y.  DRUG METABOLISM AND DISPOSITION 25 9 1039-1044 1997
  •  Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 283 2 520-527 1997
  •  Hepatobiliary transport mechanism for the cyclopentapeptide endothelin antagonist BQ-123.  Shin HC, Kato Y, Yamada T, Niinuma K, Hisaka A, Sugiyama Y.  AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY 272 (5 Pt 1) G979-G986 1997
  •  Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. Chu XY, Kato Y, Niinuma K, Sudo KI, Hakusui H, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 281 1 304-314 1997
  •  Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Chu XY, Kato Y, Sugiyama Y.  Cancer Res. 57 10 1934-1938 1997
  •  Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Masuda M, I'izuka Y, Yamazaki M, Nishigaki R, Kato Y, Ni'inuma K, Suzuki H, Sugiyama Y.  CANCER RESEARCH 57 16 3506-3510 1997
  •  Kinetic analysis of the primary active transport of conjugated metabolites across the bile canalicular membrane: comparative study of S-(2,4-dinitrophenyl)-glutathione and 6-hydroxy-5,7-dimethyl-2- methylamino-4-(3-pyridylmethyl)benzothiazole glucuronide.  Niinuma K, Takenaka O, Horie T, Kobayashi K, Kato Y, Suzuki H, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 282 2 866-872 1997
  •  Human placental extract stimulates liver regeneration in rats.  Liu KX, Kato Y, Kaku T, Sugiyama Y.  BIOLOGICAL & PHARMACEUTICAL BULLETIN 21 1 44-49 1998
  •  Importance of hepatic first-pass removal in metastasis of colon carcinoma cells: Kinetics of tumor cells. Mizuno N, Kato Y, Izumi Y, Irimura T, Sugiyama Y.  JOURNAL OF HEPATOLOGY 28 5 865-877 1998
  •  Mechanism of initial distribution of blood-borne colon carcinoma cells in the liver. Mizuno N, Kato Y, Shirota K, Izumi Y, Irimura T, Harashima H, Kiwada H, Motoji N, Shigematsu A, Sugiyama Y.  JOURNAL OF HEPATOLOGY 28 5 878-885 1998
  •  Protamine enhances the proliferative activity of hepatocyte growth factor in rats. Liu KX, Kato Y, Kaku TI, Matsumoto K, Nakamura T, Sugiyama Y.  AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY 274 1Pt1 G21-G28 1998
  •  Effect of brefeldin A and lysosomotropic reagents on intracellular trafficking of epidermal growth factor and transferrin in Madin-Darby canine kidney epithelial cells.  Shitara Y, Kato Y, Sugiyama Y.  JOURNAL OF CONTROLLED RELEASE 55 1 35-43 1998
  •  Pharmacokinetics of erythropoietin in genetically anemic mice.  Kato M, Miura K, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y.  DRUG METABOLISM AND DISPOSITION 26 2 126-131 1998
  •  Ligand-induced downregulation of receptor-mediated clearance of hepatocyte growth factor in rats. Liu KX, Kato Y, Kino I, Nakamura T, Sugiyama Y.  AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM 275 5Pt1 E835-E842 1998
  •  Characterization of the transport of a cationic octapeptide, octreotide, in rat bile canalicular membrane: possible involvement of P-glycoprotein.  Yamada T, Kato Y, Kusuhara H, Lemaire M, Sugiyama Y.  BIOLOGICAL & PHARMACEUTICAL BULLETIN 21 8 874-878 1998
  •  Stereoselective hepatobiliary transport of the quinolone antibiotic grepafloxacin and its glucuronide in the Rat. Sasabe H, Kato Y, Tsuji A, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 284 2 661-668 1998
  •  Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters. Chu XY, Kato Y, Ueda K, Suzuki H, Niinuma K, Tyson CA, Weizer V, Dabbs JE, Froehlich R, Green CE, Sugiyama Y. CANCER RESEARCH 58 22 5137-5143 1998
  •  Efficient extraction by the liver governs overall elimination of hepatocyte growth factor in rats. Kato M, Kato Y, Nakamura T, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 290 1 373-379 1999
  •  Mechanism of the upregulation of erythropoietin-induced uptake clearance by the spleen. Kato M, Kato Y, Sugiyama Y.  AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM 276 5Pt1 E887-895 1999
  •  Hepatobiliary transport governs overall elimination of peptidic endothelin antagonists in rats. Kato Y, Akhteruzzaman S, Hisaka A, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 288 2 568-574 1999
  •  Primary active transport of peptidic endothelin antagonists by rat hepatic canalicular membrane. Akhteruzzaman S, Kato Y, Hisaka A, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 288 2 575-581 1999
  •  Primary active transport of organic anions on bile canalicular membrane in humans. Niinuma K, Kato Y, Suzuki H, Tyson CA, Weizer V, Dabbs JE, Froehlich R, Green CE, Sugiyama Y.  AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY 276 5Pt1 G1153-1164 1999
  •  Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat. Sasabe H, Kato Y, Terasaki T, Tsuji A, Sugiyama Y.  BIOPHARMACEUTICS & DRUG DISPOSITION 20 3 151-158 1999
  •  Kinetic profile of overall elimination of 5-methyltetrahydropteroylglutamate in rats. Han YH, Kato Y, Kusuhara H, Suzuki H, Shimoda M, Kokue E, Sugiyama Y.  AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM 276 3Pt1 E580-E587 1999
  •  Renal handling of biphosphonate alendronate in rats. Kino I, Kato Y, Lin JH, Sugiyama Y.  BIOPHARMACEUTICS & DRUG DISPOSITION 20 4 193-198 1999
  •  Carrier-mediated hepatic uptake of peptidic endothelin antagonists in rats. Akhteruzzaman S, Kato Y, Kouzuki H, Suzuki H, Hisaka A, Stieger B, Meier PJ, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 290 3 1107-1115 1999
  •  Nonlinear disposition kinetics of a novel antifolate, MX-68, in rats. Han YH, Kato Y, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 291 1 204-212 1999
  •  Active efflux of CPT-11 and its metabolites in human KB-derived cell lines Chu XY, Suzuki H, Ueda K, Kato Y, Akiyama S, Sugiyama Y. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 288 2 735-741 1999
  •  Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats. Chu XY, Kato Y, Sugiyama Y.  DRUG METABOLISM AND DISPOSITION 27 4 440-441 1999
  •  Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1,1-dimethylethylaminocarbonyl)-4-[(furo[2,3B]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2R-phenylmethylpentanamide and P-glycoprotein by valspodar... Kawahara I, Kato Y, Suzuki H, Achira M, Ito K, Crespi CL, Sugiyama Y.  DRUG METABOLISM AND DISPOSITION 28 10 1238-1243 2000
  •  Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance- associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats.  Gotoh Y, Suzuki H, Kinoshita S, Hirohashi T, Kato Y, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 292 1 433-439 2000
  •  Binding and transport of methotrexate and its derivative, MX-68, across the brush-border membrane in the rat kidney. Han YH, Kato Y, Sugiyama Y. BIOPHARMACEUTICS & DRUG DISPOSITION 20 361-367 1999
  •  Hydroxyprolylserine derivatives JBP923 and JBP485 exhibit the antihepatitis activities after gastrointestinal absorption in rats. Liu KX, Kato Y, Kaku TI, Santa T, Imai K, Yagi A, Ishizu T, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 294 2 510-515 2000
  •  Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the non-peptide angiotensin II antagonist, Telmisaltan. Nishino A, Kato Y, Igarashi T, Sugiyama Y.  Drug Metab. Dispos. 28 10 1146-1148 2000
  •  Anti-metastatic effect of the sialyl Lewis-X analog GSC-150 on the human colon carcinoma derived cell line KM12-HX in the mouse. Shirota K, Kato Y, Irimura T, Kondo H, Sugiyama Y. BIOLOGICAL & PHARMACEUTICAL BULLETIN 24 3 316-319 2001
  •  Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system. Nishiyama N, Kato Y, Sugiyama Y, Kataoka K.  PHARMACEUTICAL RESEARCH 18 7 1035-1041 2001
  •  Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. Yamamoto Y, Nagasaki Y, Kato Y, Sugiyama Y, Kataoka K.  JOURNAL OF CONTROLLED RELEASE 77 1-2 27-38 2001
  •  Kinetic analysis of the disposition of insulin-like growth factor 1 in healthy volunteers. Mizuno N, Kato Y, Iwamoto M, Urae A, Amamoto T, Niwa T, Sugiyama Y.  PHARMACEUTICAL RESEARCH 18 8 1203-1209 2001
  •  Characterization of Novel Kidney-Specific Delivery System Using an Alkylglucoside Vector. Shirota K, Kato Y, Suzuki K, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 299 2 459-467 2001
  •  Investigation of 5-FU Disposition After Oral Administration of Capecitabine, a Triple-prodrug of 5-FU, Using a Physiologically Based Pharmacokinetic Model in a Human Cancer Xenograft Model: Comparison of the Simulated 5-FU ... Tsukamoto Y, Kato Y, Ura M, Horii I, Ishikawa T, Ishitsuka H, Sugiyama Y.  Biopharm. Drug Dispos. 22 1 1-14 2001
  •  A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Tsukamoto Y, Kato Y, Ura M, Horii I, Ishitsuka H, Kusuhara H, Sugiyama Y.  PHARMACEUTICAL RESEARCH 18 8 1190-1202 2001
  •  Physicochemical parameters responsible for the affinity of methotrexate analogs to rat canalicular multispecific organic anion transporter (cMOAT/MRP2). Han YH, Kato Y, Haramura M, Ohta M, Matsuoka H, Sugiyama Y.  PHARMACEUTICAL RESEARCH 18 5 579-586 2001
  •  Carrier-mediated hepatobiliary transport of a novel antifolate, N-[4-[(2,4-diamminopteridine-6-yl)methyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl-L-homoglutamic acid, in rats. Han YH, Kato Y, Watanabe Y, Terao K, Asoh Y, Sugiyama Y.  DRUG METABOLISM AND DISPOSITION 29 4Pt1 394-400 2001
  •  Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. Ueda K, Kato Y, Komatsu K, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 297 3 1036-1043 2001
  •  Structural basis for acidic cluster-dileucine sorting signal recognition by VHS domains. Misra S, Puertollano R, Kato Y, Bonifacino JS, Hurley JH. NATURE 415 6874 933-937 2002
  •  Phosphoregulation of sorting signal-VHS domain interactions by a direct electrostatic mechanism. Kato Y, Misra S, Puertollano R, Hurley JH, Bonifacino JS. NATURE STRUCTURAL BIOLOGY 9 7 532-536 2002
  •  A novel hepatic-targeting system for therapeutic cytokines that delivers to the hepatic asialoglycoprotein receptor, but avoids receptor-mediated endocytosis.  Sato H, Kato Y, Hayasi E, Tabata T, Suzuki M, Takahara Y, Sugiyama Y.  PHARMACEUTICAL RESEARCH 19 11 1736-1744 2002
  •  pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes.  Maeda K, Kato Y, Sugiyama Y.  JOURNAL OF CONTROLLED RELEASE 82 1 71-82 2002
  •  Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport.  Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y.  PHARMACEUTICAL RESEARCH 19 2 147-153 2002
  •  The Potential for an Interaction between MRP2 (ABCC2) and Various Therapeutic Agents: Probenecid as a Candidate Inhibitor of the Biliary Excretion of Irinotecan Metabolites.  Horikawa M, Kato Y, Tyson CA, Sugiyama Y.  DRUG METABOLISM AND PHARMACOKINETICS 17 1 23-33 2002
  •  Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.  Horikawa M, Kato Y, Sugiyama Y.  PHARMACEUTICAL RESEARCH 19 9 1345-1353 2002
  •  Gender difference in the Oatp1-mediated tubular reabsorption of estradiol 17beta-D-glucuronide in rats. Gotoh Y, Kato Y, Stieger B, Meier PJ, Sugiyama Y.  AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM 282 6 E1245-E1254 2002
  •  Gender difference in the urinary excretion of organic anions in rats. Kato Y, Kuge K, Kusuhara H, Meier PJ, Sugiyama Y. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 302 2 483-9 2002
  •  Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin.  Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 302 2 510-515 2002
  •  Mechanism for the tissue distribution of grepafloxacin, a fluoroquinolone antibiotic, in rats.  Suzuki T, Kato Y, Sasabe H, Itose M, Miyamoto G, Sugiyama Y.  DRUG METABOLISM AND DISPOSITION 30 12 1393-1399 2002
  •  Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice.  Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y, Nishio K, Matsumura Y, Kataoka K.  CANCER RESEARCH 63 24 8977-8983 2003
  •  Recognition of dileucine-based sorting signals from HIV-1 Nef and LIMP-II by the AP-1 gamma-sigma1 and AP-3 delta-sigma3 hemicomplexes. Janvier K, Kato Y, Boehm M, Rose JR, Martina JA, Kim BY, Venkatesan S, Bonifacino JS. JOURNAL OF CELL BIOLOGY 163 6 1281-1290 2003
  •  Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans.  Horikawa M, Kato Y, Tyson CA, Sugiyama Y.  DRUG METABOLISM AND PHARMACOKINETICS 18 1 16-22 2003
  •  Function of uptake transporters for taurocholate and estradiol 17beta-d-glucuronide in cryopreserved human hepatocytes.  Shitara Y, Li AP, Kato Y, Lu C, Ito K, Itoh T, Sugiyama Y.  DRUG METABOLISM AND PHARMACOKINETICS 18 1 33-41 2003
  •  Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin.  Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y.  MOLECULAR PHARMACOLOGY 63 4 844-848 2003
  •  Influence of drugs and nutrients on transporter gene expression levels in Caco-2 and LS180 intestinal epithelial cell lines.  Li Q, Sai Y, Kato Y, Tamai I, Tsuji A.  PHARMACEUTICAL RESEARCH 20 8 1119-1124 2003
  •  Involvement of multiple transport systems in the disposition of an active metabolite of a prodrug-type new quinolone antibiotic, prulifloxacin.  Yagi Y, Shibutani S, Hodoshima N, Ishiwata K, Okudaira N, Li Q, Sai Y, Kato Y, Tsuji A.  DRUG METABOLISM AND PHARMACOKINETICS 18 6 381-389 2003
  •  Transporter-mediated renal handling of nafamostat mesilate.  Li Q, Sai Y, Kato Y, Muraoka H, Tamai I, Tsuji A.  JOURNAL OF PHARMACEUTICAL SCIENCES 93 2 262-272 2004
  •  Functional regions of organic cation/carnitine transporter OCTN2 (SLC22A5): roles in carnitine recognition.  Inano A, Sai Y, Kato Y, Tamai I, Ishiguro M, Tsuji A.  DRUG METABOLISM AND PHARMACOKINETICS 19 3 180-189 2004
  •  Characterization of renal excretion mechanism for a novel diuretic, M17055, in rats.  Nishimura T, Kato Y, Sai Y, Ogihara T, Tsuji A.  JOURNAL OF PHARMACEUTICAL SCIENCES 93 10 2558-2566 2004
  •  Differential involvement of multidrug resistance-associated protein 1 and P-glycoprotein in tissue distribution and excretion of grepafloxacin in mice. Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 310 2 648 2004
  •  Functional characterization of human organic cation transporter OCTN1 single nucleotide polymorphisms in the Japanese population.  Kawasaki Y, Kato Y, Sai Y, Tsuji A.  JOURNAL OF PHARMACEUTICAL SCIENCES 93 12 2920-2926 2004
  •  Screening of the interaction between xenobiotic transporters and PDZ proteins Kato Y, Yoshida K, Watanabe C, Sai Y, Tsuji A.  PHARMACEUTICAL RESEARCH 21 10  1886-1894 2004
  •  Carrier-mediated uptake of grepafloxacin, a fluoroquinolone antibiotic, by the isolated rat lung cells. Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sugiyama Y. DRUG METABOLISM AND PHARMACOKINETICS 20 6 491-495 2005
  •  Multidrug resistance-associated protein 1 functions as an efflux pump of xenobiotics in the skin.  Li Q, Kato Y, Sai Y, Imai T, Tsuji A. PHARMACEUTICAL RESEARCH 22 6 842-846 2005
  •  PDZK1 directly regulates the function of organic cation/carnitine transporter OCTN2. Kato Y, Sai Y, Yoshida K, Watanabe C, Hirata T, Tsuji A. MOLECULAR PHARMACOLOGY 67 3  734-743 2005
  •  Na+/ H+ exchanger 3 affects transport property of H+/oligopeptide transporter 1. Watanabe C, Kato Y, Ito S, Kubo Y, Sai Y and Akira Tsuji. DRUG METABOLISM AND PHARMACOKINETICS 20 6 443-451 2005
  •  A time- and cost-saving method of producing rat polyclonal antibodies. Wakayama T, Kato Y, Utsumi R, Tsuji A, Iseki S. ACTA HISTOCHEMICA ET CYTOCHEMICA 39 3 79-87 2006
  •  Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice. Jin M, Shimada T, Yokogawa K, Nomura M, Ishizaki J, Piao Y, Kato Y, Tsuji A, Miyamoto K. BIOCHEMICAL PHARMACOLOGY 72 8 1042-1050 2006
  •  Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone. Jin M, Shimada T, Yokogawa K, Nomura M, Kato Y, Tsuji A, Miyamoto K. INTERNATIONAL JOURNAL OF PHARMACEUTICS 309 1-2 81-86 2006
  •  Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I, Artursson P, Tsuji A. DRUG METABOLISM AND DISPOSITION 34 8 1423-1431 2006
  •  Carrier-mediated hepatic uptake of a novel non-renal excretion type uric acid generation inhibitor, Y-700. Sai Y, Kato Y, Nakamura K, Kato S, Nishimura T, Kubo Y, Tamai I, Yang S, Hu Z, Yamada I and Tsuji A. JOURNAL OF PHARMACEUTICAL SCIENCES 95 2 336-347 2006
  •  Characterization of the transdermal transport of flurbiprofen and indomethacin. Li Q, Tsuji H, Kato Y, Sai Y, Kubo Y, Tsuji A. JOURNAL OF CONTROLLED RELEASE 110 3 542-556 2006
  •  Mutation in an adaptor protein PDZK1 affects transport activity of organic cation transporter OCTNs and oligopeptide transporter PEPT2. Sugiura T, Kato Y, Kubo Y and Tsuji A. DRUG METABOLISM AND PHARMACOKINETICS 21 5 375-383 2006
  •  PDZ adaptor protein PDZK2 stimulates transport activity of organic cation/carnitine transporter OCTN2 by modulating cell-surface expression. Watanabe C, Kato Y, Sugiura T, Kubo Y, Wakayama T, Iseki S and Tsuji A. DRUG METABOLISM AND DISPOSITION 34 11 1927-1934 2006
  •  Organic cation/carnitine transporter OCTN2 (Slc22a5) is responsible for carnitine transport across apical membranes of small intestinal epithelial cells in mouse. Kato Y, Sugiura M, Sugiura T, Wakayama T, Kubo Y, Kobayashi D, Sai Y, Tamai I, Iseki S, Tsuji A. MOLECULAR PHARMACOLOGY 70 3 829-837 2006
  •  Heterophilic binding of the adhesion molecules poliovirus receptor and immunoglobulin superfamily 4A in the interaction between mouse spermatogenic and Sertoli cells. Wakayama T, Sai Y, Ito A, Kato Y, Kurobo M, Murakami Y, Nakashima E, Tsuji A, Kitamura Y, Iseki S. BIOLOGY OF REPRODUCTION 76 6 1081-1090 2007
  •  Characterization of the hepatic disposition of lanoteplase, a rationally designed variant of tissue plasminogen activator in rodents. Komoriya K, Kato Y, Hayashi Y, Ohsuye K, Nishigaki R, Sugiyama Y.  DRUG METABOLISM AND DISPOSITION 35 3 469-475 2007
  •  Characterization of the uptake mechanism for a novel loop diuretic, M17055, in Caco-2 cells: Involvement of organic anion transporting polypeptide (OATP)-B. Nishimura T, Kubo Y, Kato Y, Sai Y, Ogihara T and Tsuji A.  PHARMACEUTICAL RESEARCH 24 1 90-98 2007
  •  Functional expression of stereoselective metabolism of cephalexin by exogenous transfection of oligopeptide transporter PEPT1. Mitsuoka K, Kato Y, Kubo Y, Tsuji A.  DRUG METABOLISM AND DISPOSITION 35 3 356-362 2007
  •  Transporter-mediated Hepatic Uptake of Ulifloxacin, an Active Metabolite of a Prodrug-type New Quinolone Antibiotic Prulifloxacin in Rats. Yagi Y, Aoki M, Iguchi M, Shibasaki S, Kurosawa T, Kato Y, Tsuji A. DRUG METABOLISM AND PHARMACOKINETICS 22 5 350-357 2007
  •  Involvement of organic anion transport system in transdermal absorption of flurbiprofen. Ito K, Kato Y, Tsuji H, Nguyen HT, Kubo Y, Tsuji A. JOURNAL OF CONTROLLED RELEASE 124 1-2 60-68 2007
  •  Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. Nishimura T, Amano N, Kubo Y, Ono M, Kato Y, Fujita H, Kimura Y, Tsuji A.  DRUG METABOLISM AND DISPOSITION 35 8 1275-1284 2007
  •  The Rab8 GTPase regulates apical protein localization in intestinal cells. Sato T, Mushiake S, Kato Y, Sato K, Sato M, Takeda N, Ozono K, Miki K, Kubo Y, Tsuji A, Harada R, Harada A.  NATURE 448 7151 366-369 2007
  •  Cancer detection using a PET tracer, 11C-glycylsarcosine, targeted to H+/peptide transporter. Mitsuoka K, Miyoshi S, Kato Y, Murakami Y, Utsumi R, Kubo Y, Hiraiwa M, Noda A, Nakamura Y, Nishimura S, Tsuji A.  JOURNAL OF NUCLEAR MEDICINE 49 4 615-622 2008
  •  Cationic Polyrotaxanes effectively inhibit Uptake via Carnitine/Organic Cationic Transporter without cytotoxicity. Utsunomiya H, Katoono R, Yui N, Sugiura T, Kubo Y, Kato Y, Tsuji A. MACROMOLECULAR BIOSCIENCE 8 7 665-669 2008
  •  PDZK1 regulates two intestinal solute carriers (Slc15a1 and Slc22a5) in mice. Sugiura T, Kato Y, Wakayama T, Silver DL, Kubo Y, Iseki S, Tsuji A. DRUG METABOLISM AND DISPOSITION 36 6 1181-1188 2008
  •  Involvement of carnitine/organic cation transporter OCTN2 (SLC22A5) in distribution of its substrate carnitine to the heart. Iwata D, Kato Y, Wakayama T, Sai Y, Kubo Y, Iseki S, Tsuji A. DRUG METABOLISM AND PHARMACOKINETICS 23 3 207-215 2008
  •  Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. Kato Y, Takahara S, Kato S, Kubo Y, Sai Y, Tamai I, Yabuuchi H, Tsuji A. DRUG METABOLISM AND DISPOSITION 36 6 1088-1096 2008
  •  Species difference in intestinal absorption mechanism of etoposide and digoxin between cynomolgus monkey and rat. Nishimura T, Kato Y, Amano N, Ono M, Kubo Y, Kimura Y, Fujita H, Tsuji A. PHARMACEUTICAL RESEARCH 25 11 2467-2476 2008
  •  L-type fatty acid binding protein transgenic mouse as a novel tool to explore cytotoxicity to renal proximal tubules. Nakamura K, Ito K, Kato Y, Sugaya T, Kubo Y, Tsuji A. DRUG METABOLISM AND PHARMACOKINETICS 23 4 271-278 2008
  •  P-Glycoprotein (Abcb1) is involved in absorptive drug transport in skin. Ito K, Nguyen H-T, Kato Y, Wakayama T, Kubo Y, Iseki S, Tuji A. JOURNAL OF CONTROLLED RELEASE 131 3 198-204 2008
  •  Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. Kato Y, Miyazaki T, Kano T, Sugiura T, Kubo Y, Tsuji A. JOURNAL OF PHARMACEUTICAL SCIENCES 98 7 2529-2539 2009
  •  Investigation of the role of oligopeptide transporter PEPT1 and sodium/glucose cotransporter SGLT1 in intestinal absorption of their substrates using small GTP-binding protein Rab8 null mice. Kato Y, Sugiura T, Nakadera Y, Sugiura M, Kubo Y, Sato T, Harada A, Tsuji A. DRUG METABOLISM AND DISPOSITION 37 3 602-607 2009
  •  Characterization of the enhancing effect of protamine on the proliferative activity of hepatocyte growth factor in rat hepatocytes. Liu KX, Kato Y, Matsumoto K, Nakamura T, Kaku T, Sugiyama Y. PHARMACEUTICAL RESEARCH 26 4 1012-1021 2009
  •  Carnitine/organic cation transporter OCTN2 (Slc22a5) is responsible for renal secretion of cephaloridine in mice. Kano T, Kato Y, Ito K, Ogihara T, Kubo Y, Tsuji A. DRUG METABOLISM AND DISPOSITION 37 5  1009-16 2009
  •  Involvement of multidrug resistance-associated protein 1 in intestinal toxicity of methotrexate. Kato S, Ito K, Kato Y, Wakayama T, Kubo Y, Iseki S, Tsuji A. PHARMACEUTICAL RESEARCH 26 6  1467-1476 2009
  •  Direct evidence for efficient transport and minimal metabolism of l-Cephalexin by PEPT1 in budded baculovirus fraction.  Mitsuoka K, Tamai I, Morohashi Y, Kubo Y, Saitoh R, Tsuji A, Kato Y.  BIOLOGICAL & PHARMACEUTICAL BULLETIN 32 8  1459-1461 2009
  •  Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice. Kato S, Kato Y, Nakamura T, Sugiura T, Kubo Y, Deguchi Y, Tsuji A.  BIOPHARMACEUTICS & DRUG DISPOSITION 30 9 495-507 2009
  •  Gene knockout and metabolome analysis of carnitine/organic cation transporter OCTN1.  Kato Y, Kubo Y, Iwata D, Kato S, Sudo T, Sugiura T, Kagaya T, Wakayama T, Hirayama A, Sugimoto M, Sugihara K, Kaneko S, Soga T, Asano M, Tomita M, Matsui T, Wada M, Tsuji A.  PHARMACOLOGICAL RESEARCH 27 5 832-840 2010
  •  Inhibition of oligopeptide transporter suppress growth of human pancreatic cancer cells.  Mitsuoka K, Kato Y, Miyoshi S, Murakami Y, Hiraiwa M, Kubo Y, Nishimura S, Tsuji A.  EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 40 3 202-208 2010
  •  OCTN2 is associated with carnitine transport capacity of rat skeletal muscles.  Furuichi Y, Sugiura T, Kato Y, Shimada Y, Masuda K.  200 1 57-64 2010
  •  Functional expression of carnitine/organic cation transporter OCTN1/SLC22A4 in mouse small intestine and liver.  Sugiura T, Kato S, Shimizu T, Wakayama T, Nakamichi N, Kubo Y, Iwata D, Suzuki K, Soga T, Asano M, Iseki S, Tamai I, Tsuji A, Kato Y.  DRUG METABOLISM AND DISPOSITION 38 10 1665-1672 2010
  •  Molecular mechanisms of biliary excretion of cefditoren and the effects of cefditoren on the expression levels of hepatic transporters.  Meng Q, Liu Q, Wang C, Sun H, Kaku T, Kato Y, Liu K.  25 4 320-327 2010
  •  PDZK1 regulates organic anion transporting polypeptide Oatp1a in mouse small intestine.  Sugiura T, Otake T, Shimizu T, Wakayama T, Silver DL, Utsumi R, Nishimura T, Iseki S, Nakamichi N, Kubo Y, Tsuji A, Kato Y.  DRUG METABOLISM AND PHARMACOKINETICS 25 6 588-598 2010
  •  Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-Increasing agent.  Takeuchi K, Sugiura T, Umeda S, Matsubara K, Horikawa M, Nakamichi N, Silver DL, Ishiwata N, Kato Y.  DRUG METABOLISM AND DISPOSITION 39 6 1088-1096 2011
  •  Effect of knockdown of ezrin, radixin and moesin on P-glycoprotein function in HepG2 cells. Kano T, Wada S, Morimoto K, Kato Y, Ogihara T. JOURNAL OF PHARMACEUTICAL SCIENCES 100 12 5308-5314 2011
  •  PDZK1 Regulates Breast Cancer Resistance Protein in Small Intestine.  Shimizu T, Sugiura T, Wakayama T, Kijima A, Nakamichi N, Iseki S, Silver DL, Kato Y.  DRUG METABOLISM AND DISPOSITION 印刷中 印刷中 印刷中 2011
  •  Muscle contraction increases carnitine uptake via translocation of OCTN2. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 418 4 774-779 2012
  •  Functional expression of carnitine/organic cation transporter OCTN1 in mouse brain neurons: Possible involvement in neuronal differentiation.  NEUROCHEMISTRY INTERNATIONAL 61 7 1121-1132 2012
  •  Pharmacokinetic modeling of hepatocyte growth factor in experimental animals and humans.  JOURNAL OF PHARMACEUTICAL SCIENCES 102 1 237-249 2013
  •  ATP binding cassette transporters in two distinct compartments of skin contribute to transdermal absorption of a typical substrate. JOURNAL OF CONTROLLED RELEASE 165 1 54-61 2013
  •  Role of organic cation/carnitine transporter 1 in uptake of phenformin and inhibitory effect on complex I respiration in mitochondria. TOXICOLOGICAL SCIENCES 132 1 32-42 2013
  •  Displays of mouse pup retrieval as paternal parental behaviour following communicative interaction with maternal mates. Liu H-X, Lopatina O, Higashida C, Fujimoto H, Akther S, Inzhutova A, Liang M, Zhong J, Tsuji T, Yoshihara T, Sumi K, Ishiyama M, Ma W-J, Ozaki M, Yagitani S, Yokoyama S, Mukaida N, Sakurai T, Hori O, Yoshioka K, Hirao A, Kato Y, Ishihara K, Kato I, Okamoto H, Cherepanov SM, Salmina A, Hirai H, Asano M, Brown DA, Nagano I, Higashida H.  Nat Commun 4 1346 2013
  •  Contribution of radixin to P-glycoprotein expression and transport activity in mouse small intestine in vivo. Yano K, Tomono T, Sakai R, Kano T, Morimoto K, Kato Y, Ogihara T.  J Pharm Sci 102 8 2875-2881 2013
  •  Involvement of carnitine/organic cation transporter OCTN1/SLC22A4 in gastrointestinal absorption of metformin. Nakamichi N, Shima H, Asano S, Ishimoto T, Sugiura T, Matsubara K, Kusuhara H, Sugiyama Y, Sai Y, Miyamoto KI, Tsuji A, Kato Y.  J Pharm Sci 102(9): , 2013. 102 9 3407-3417 2013
  •  A common missense variant of monocarboxylate transporter 9 (MCT9/SLC16A9) gene is associated with renal overload gout, but not with all gout susceptibility. Nakayama A, Matsuo H, Shimizu T, Ogata H, Takada Y, Nakashima H, Nakamura T, Shimizu S, Chiba T, Sakiyama M, Ushiyama C, Takada T, Inoue K, Kawai S, Hishida A, Wakai K, Hamajima N, Ichida K, Sakurai Y, Kato Y, Shimizu T, Shinomiya N.  Hum Cell 26 4 133-136 2013
  •  Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans.  Fujita K, Sugiura T, Okumura H, Umeda S, Nakamichi N, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Sasaki Y and Kato Y.  Pharm Res 31 31 1 204-215 2014
  •  Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in human.  Takeuchi K, Sugiura T, Matsubara K, Sato R, Shimizu T, Masuo Y, Horikawa M, Nakamichi N, Ishiwata N and Kato Y. Drug Metab Dispos 42 4 726-734 2014
  •  Organic cation transporter-mediated ergothioneine uptake in mouse neural progenitor cells suppresses proliferation and promotes differentiation into neurons.  IshimotoT, Nakamichi N, Hosotani H, Masuo Y, Sugiura T and Kato Y.  PLoS One 9 2 e89434 2014
  •  Pharmacokinetics and pharmacodynamics following intravenous administration of recombinant human hepatocyte growth factor in rats with renal injury.  Adachi E, Hirose-Sugiura T, Kato Y, Ikebuchi F, Yamashita A, Abe T, Fukuta K, Adachi K and Matsumoto K.  Pharmacology 94 3-4 190-187 2014
  •  Distinct Alterations in ABC Transporter Expression in Liver, Kidney, Small Intestine, and Brain in Adjuvant-induced Arthritic Rats. Kawase A, Norikane S, Okada A, Adachi M, Kato Y, Iwaki M.  J Pharm Sci 103 8 2556-2564 2014
  •  Decreased radixin function for ABC transporters in liver in adjuvant-induced arthritis rats.  Kawase A, Sakata M, Yada N, Nakasaka M, Shimizu T, Kato Y, Iwaki M.  J Pharm Sci 103 12 4058-4065 2014
  •  Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes.  Matsuo H, Yamamoto K, Nakaoka H, Nakayama A, Sakiyama M, Chiba T, Takahashi A, Nakamura T, Nakashima H, Takada Y, Danjoh I, Shimizu S, Abe J, Kawamura Y, Terashige S, Ogata H, Tatsukawa S, Yin G, Okada R, Morita E, Naito M, Tokumasu A, Onoue H, Iwaya K, Ito T, Takada T, Inoue K, Kato Y, Nakamura Y, Sakurai Y, Suzuki H, Kanai Y, Hosoya T, Hamajima N, Inoue I, Kubo M, Ichida K, Ooyama H, Shimizu T, Shinomiya N.  Ann Rheum Dis 75 4 652-659 2016
  •  Organic Cation Transporter Octn1-mediated Uptake of Food-derived Antioxidant Ergothioneine into Infiltrating Macrophages during Intestinal Inflammation in Mice.  Shimizu T, Masuo Y, Takahashi S, Nakamichi N and Kato Y.  Drug Metab Pharmacokinet 30 3 231-239 2015
  •  Gene ablation of carnitine/organic cation transporter 1 reduces gastrointestinal absorption of 5-aminosalicylate in mice.  Shimizu T, Kijima A, Masuo Y, Ishimoto T, Sugiura T, Takahashi S, Nakamichi N, Kato Y.  Chem Pharm Bull 38 5 774-780 2015
  •  Dipeptide species regulate nutrient signalling essential for the maintenance of chronic myelogenous leukaemia stem cells. Naka K, Jomen Y, Ishihara K, Kim J, Ishimoto T, Bae E, Mohney R, Stirdivant SM, Oshima H, Oshima M, Kim DW, Nakauchi H, Takihara Y, Kato Y, Ooshima A, Kim SJ.  Nat Commun 6 8039 2015
  •  Increased plasma concentrations of unbound SN-38, the active metabolite of irinotecan, in cancer patients with severe renal failure.  Fujita K, Masuo Y, Okumura H, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Akiyama Y, Kitamura M, Kunishima M, Sasaki Y, Kato Y.  Pharm Res 33 2 269-282 2016
  •  Myoglobin and the Regulation of Mitochondrial Respiratory Chain Complex IV.  Yamada T, Takakura H, Jue T, Hashimoto T, Ishizawa R, Furuichi Y, Kato Y, Iwanaka N, Masuda K.  J Physiol  594 2 483-495 2016
  •  Localizatoin of xenobiotic transporter OCTN1/SLC22A4 in hepatic stellate cells and its protective role in liver fibrosis. Tang Y, Masuo Y, Sakai Y, Wakayama T, Sugiura T, Harada R, Futatsugi A, Komura T, Nakamichi N, Sekiguchi H, Sutoh K, Usumi K, Iseki S, Kaneko S, Kato Y.  J Pharm Sci 105 5 1779-1789 2016
  •  Transport of 3-fluoro-L--methyl-tyrosine (FAMT) by organic ion transporters explains renal background in [18F]FAMT positron emission tomography.  Wei L, Tominaga H, Ohgaki R, Wiriyasermkul P, Hagiwara K, Okuda S, Kaira K, Kato Y, Oriuchi N, Nagamori S, Kanai Y.  J Pharmacol Sci 130 2 101-109 2016
  •  A mutation in SLC22A4 encoding an organic cation transporter expressed in the cochlea strial endothelium causes human recessive non-syndromic hearing loss DFNB60. Ben Said M, Grati M, Ishimoto T, Zou B, Chakchouk I, Ma Q, Yao Q, Hammami B, Yan D, Mittal R, Nakamichi N, Ghorbel A, Neng L, Tekin M, Shi XR, Kato Y, Masmoudi S, Lu Z, Hmani M, Liu X.  Human Genetics 135 5 513-524 2016
  •  Food-derived hydrophilic antioxidant ergothioneine is distributed to the brain and exerts antidepressant effect in mice. Nakamichi N, Nakayama K, Ishimoto T, Masuo Y, Wakayama T, Sekiguchi H, Sutoh K, Usumi K, Iseki S, Kato Y.  Brain and Behavior 6 6 e00477 2016
  •  Characterization of long-lasting Oatp inhibition by typical inhibitor cyclosporine A and in vitro-in vivo discrepancy in its drug interaction potential in rats.  Taguchi T, Masuo Y, Kogi T, Nakamichi N, Kato Y.  J Pharm Sci 105(7): , 2016. 105 7 2231-2239 2016
  •  L503F variant of carnitine/organic cation transporter 1 efficiently transports metformin and other biguanides.  Futatsugi A, Masuo Y, Kawabata S, Nakamichi N, Kato Y.  J Pharm Pharmacol 68 9 1160-1169 2016
  •  Screening to identify multidrug resistance-associated protein inhibitors with neuroblastoma-selective cytotoxicity. Nakamichi N, Ishimoto T, Yamauchi Y, Masuo Y, Kato Y.  Biol Pharm Bull 39 10 1638-1645 2016
  •  Preventive effect of salicylate and pyridoxamine on diabetic nephropathy.  Abouzed TK, Munesue S, Harashima A, Masuo Y, Kato Y, Kahilo KKK, Yamamoto H, Yamamoto Y.  J Diabetes Res Article ID 1786789, 2016 2016
  •  P-Glycoprotein in skin contributes to transdermal absorption of topical corticosteroids.  Hashimoto N, Nakamichi N, Yamazaki E, Oikawa M, Masuo Y, Schinkel AH, Kato Y.  Int J Pharm  521 (1-2) :365-373 2017
  •  Utilization of liver microsomes to estimate hepatic intrinsic clearance of monoamine oxidase substrate drugs in humans.  Masuo Y, Nagamori S, Hasegawa A, Hayashi K, Isozumi N, Nakamichi N, Kanai Y, Kato Y.  Pharm Res  34 6 1233-1243 2017
  •  Involvement of the transporters P-glycoprotein and breast cancer resistance protein in dermal distribution of the multi-kinase inhibitor regorafenib and its active metabolites. Fujita K, Masuo Y, Yamazaki E, Shibutani T, Kubota Y, Nakamichi N, Sasaki Y, Kato Y. J Pharm Sci  106 9 2632-2641 2017
  •  Impairment of the carnitine/organic cation transporter 1-ergothioneine axis is mediated by intestinal transporter dysfunction in chronic kidney disease.  Shinozaki Y, Furuichi K, Toyama T, Kitajima S, Hara A, Iwata Y, Sakai N, Shimizu M, Kaneko S, Isozumi N, Nagamori S, Kanai Y, Sugiura T, Kato Y, Wada T.  Kid Int  92 6 1356-1369 2017
  •  Usefulness of kidney slices for functional analysis of apical reabsorptive transporters. Arakawa H, Washio I, Matsuoka N, Kubo H, Staub AY, Nakamichi N, Ishiguro N, Kato Y, Nakanishi T, Tamai I.  Sci Rep  7 1 12814 2017
  •  Carnitine/organic cation transporter OCTN1 negatively regulates activation in murine cultured microglial cells.  Ishimoto T, Nakamichi N, Nishijima H, Masuo Y, Kato Y.  Neurochem Res  43 1 107-119 2018
  •  Organic cation transporter 1 is responsible for hepatocellular uptake of the tyrosine kinase inhibitor pazopanib.  Ellawatty WEA, Masuo Y, Fujita K, Yamazaki E, Ishida H, Arakawa H, Nakamichi N, Abdelwahed R, Sasaki Y, Kato Y.  46 1 33-40 2018
  •  Evaluation of alteration in hepatic and intestinal BCRP function in vivo due to ABCG2 c.421C>A polymorphism based on PBPK analysis of rosuvastatin.  Futatsugi A, Toshimoto K, Yoshikado T, Sugiyama Y, Kato Y.  Drug Metab Dispos  46 5 749-757 2018
  •  Combination metabolomics approach for identifying endogenous substrates of carnitine/organic cation transporter OCTN1. Masuo Y, Ohba Y, Yamada K, Al-Shammari AH, Seba N, Nakamichi N, Ogihara T, Kunishima M, Kato Y. Pharm Res 35 11 224 2018
  •  Effects of osthol isolated from cnidium monnieri fruit on urate transporter. Tashiro Y, Sakai R, Hirose-Sugiura T, Kato Y, Matsuo H, Takada T, Suzuki H, Makino T.  Molecules  23 11 2018
  •  Effect of coadministration of rifampicin on the pharmacokinetics of linezolid: clinical and animal studies. Hashimoto S, Honda K, Fujita K, Miyachi Y, Isoda K, Misaka K, Suga Y, Kato S, Tsuchiya H, Kato Y, Okajima M, Taniguchi T, Shimada T, Sai Y.  J Pharm Health Care Sci  40 27 2018
  •  Ergothioneine-induced neuronal differentiation is mediated through activation of S6K1 and neurotrophin 4/5-TrkB signaling in murine neural stem cells.   Ishimoto T, Masuo Y, Kato Y, and Nakamichi N.  Cell Signal  53 269-280 2018
  •  Hydrolyzed salmon milt extract enhances object recognition and location memory through an increase in hippocampal cytidine nucleoside levels in normal mice Nakamichi N, Nakao S, Masuo Y, Koike A, Matsumura N, Nishiyama M, Al-Shammari AH, Sekiguchi H, Sutoh K, Usumi K, Kato Y J Med Food 22 4 408-415 2019
  •  Influx and efflux transporters contribute to the increased dermal exposure to active metabolite of regorafenib after repeated oral administration. Al-Shammari AH, Masuo Y, Fujita K, Yoshikawa Y, Nakamichi N, Kubota Y, Sasaki Y, Kato Y.  J Pharm Sci 108 6 2173-2179 2019
  •  Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38.  Iwase M, Fujita K, Nishimura Y, Seba N, Masuo Y, Ishida H, Kato Y, Kiuchi Y.  Cancer Chemother Pharmacol 83 5 993-998 2019
  •  Bile duct obstruction leads to increased intestinal expression of breast cancer resistance protein with reduced gastrointestinal absorption of imatinib.  Kawanishi T, Arakawa H, Masuo Y, Nakamichi N, Kato Y. J Pharm Sci  108 9 3130-3137 2019
  •  Maturational characterization of mouse cortical neurons three-dimensionally cultured in functional polymer FP001-containing medium. Nakamichi N, Matsumoto Y, Kawanishi T, Ishimoto T, Masuo Y, Horikawa M, Kato Y.  Biol Pharm Bull  42 9 1545-1553 2019
  •  Short-lasting inhibition of hepatic uptake transporter OATP1B1 by tyrosine kinase inhibitor pazopanib. aguchi T, Masuo Y, Sakai Y, Kato Y. Drug Metab Pharmacokinet 364 6 372-379 2019
  •  Metabolome analysis reveals dermal histamine accumulation in murine dermatitis provoked by genetic deletion of P-glycoprotein and breast cancer resistance protein.  Hashimoto N, Nakamichi N, Nanmo H, Kimura K, Masuo Y, Sakai Y, Schinkel AH, Sato S, Soga T, Kato Y. Pharm Res 36 11 158 2019
  •  Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters. Miyake T,Mizuno T,Takehara I,Mochizuki T,Kimura M,Matsuki S,Irie S,Watanabe N,Kato Y,Ieiri I,Maeda K,Ando O,Kusuhara H Drug metabolism and disposition: the biological fate of chemicals 47 11 1270 2019/11
  •  High-speed SICM for the visualization of nanoscale dynamic structural changes in hippocampal neurons.  Takahashi Y, Zhou Y, Miyamoto T, Higashi H, Nakamichi N, Takeda Y, Kato Y, Korchev YE, Fukuma T Anal Chem 92 2 2159-2167 2020
  •  Kinetic analysis of sequential metabolism of triazolam and its extrapolation to humans using an entero-hepatic two-organ microphysiological system.  Arakawa H, Sugiura S, Kawanishi T, Shin K, Toyoda H, Satoh T, Sakai Y, Kanamori T, Kato Y Lab on a Chip 20 3 537 - 547 2020
  •  Higher systemic exposure to unbound active metabolites of regorafenib is associated with short progression-free survival in colorectal cancer patients. Yutaro Kubota,Ken-Ichi Fujita,Takehiro Takahashi,Yu Sunakawa,Hiroo Ishida,Kazuyuki Hamada,Wataru Ichikawa,Takuya Tsunoda,Kazuhiro Shimada,Yusuke Masuo,Yukio Kato,Yasutsuna Sasaki Clinical pharmacology and therapeutics 108 3 586 2020/02/08
  •  Physiologically Based Pharmacokinetic Model of the DPP-4 Inhibitor Linagliptin to Describe its Nonlinear Pharmacokinetics in Humans Akiko Sarashina,Koji Chiba,Shinji Tatami,Yukio Kato Journal of Pharmaceutical Sciences 109 7 2336 2020/07
  •  Effect of ergothioneine on the cognitive function improvement in healthy volunteers and mild cognitive impairment subjects: A randomized double-blind parallel-group comparison study (Japanese) Watanabe N, Matsumoto S, Suzuki M, Fukaya T, Kato Y, Hashiya N Jpn Pharmacol Ther 48 4 685 2020
  •  Analysis of hiPSCs differentiation toward hepatocyte-like cells upon extended exposition to oncostatin Mathieu Danoy,Yannick Tauran,Stéphane Poulain,Hiroshi Arakawa,Daiki Mori,Karin Araya,Sachi Kato,Taketomo Kido,Hiroyuki Kusuhara,Yukio Kato,Atsushi Miyajima,Charles Plessy,Yasuyuki Sakai,Eric Leclerc Differentiation 114 36 2020/07
  •  Combinational therapy with antibiotics and antibiotic-loaded adipose-derived stem cells reduce abscess formation in implant-related infection in rats. Junya Yoshitani,Tamon Kabata,Hiroshi Arakawa,Yukio Kato,Takayuki Nojima,Katsuhiro Hayashi,Masaharu Tokoro,Naotoshi Sugimoto,Yoshitomo Kajino,Daisuke Inoue,Ken Ueoka,Yuki Yamamuro,Hiroyuki Tsuchiya Scientific reports 10 1 11182 2020/07/07
  •  Static Model-Based Assessment of OATP1B1-Mediated Drug Interactions with Preincubation-Dependent Inhibitors Based on Inactivation and Recovery Kinetics. Takayuki Taguchi,Yusuke Masuo,Azusa Futatsugi,Yukio Kato Drug metabolism and disposition: the biological fate of chemicals 48 9 750 2020/09
  •  Possible utility of peptide-transporter-targeting [19F]dipeptides for visualization of the biodistribution of cancers by nuclear magnetic resonance imaging. Hiroshi Arakawa,Hiroyuki Yamada,Kazutaka Arai,Takumi Kawanishi,Nobuhiro Nitta,Sayaka Shibata,Eiko Matsumoto,Kentaro Yano,Yukio Kato,Takuya Kumamoto,Ichio Aoki,Takuo Ogihara International journal of pharmaceutics 586 119575 2020/08/30
  •  Homostachydrine is a Xenobiotic Substrate of OCTN1/SLC22A4 and Potentially Sensitizes Pentylenetetrazole-Induced Seizures in Mice. Misa Nishiyama,Noritaka Nakamichi,Tomoyuki Yoshimura,Yusuke Masuo,Tomoe Komori,Takahiro Ishimoto,Jun-Ichi Matsuo,Yukio Kato Neurochemical research 45 11 2664 2020/11
  •  Oral Administration of the Food-Derived Hydrophilic Antioxidant Ergothioneine Enhances Object Recognition Memory in Mice. Noritaka Nakamichi,Shunsuke Nakao,Misa Nishiyama,Yuka Takeda,Takahiro Ishimoto,Yusuke Masuo,Satoshi Matsumoto,Makoto Suzuki,Yukio Kato Current molecular pharmacology 14 2 220 2021
  •  6-Hydroxyindole is an endogenous long-lasting OATP1B1 inhibitor elevated in renal failure patients. Yusuke Masuo,Ken-Ichi Fujita,Kenji Mishiro,Natsumi Seba,Tatsuya Kogi,Hidenori Okumura,Natsumi Matsumoto,Munetaka Kunishima,Yukio Kato Drug metabolism and pharmacokinetics 35 6 555 2020/12
  •  Effects of Probenecid on Hepatic and Renal Disposition of Hexadecanedioate, an Endogenous Substrate of Organic Anion Transporting Polypeptide 1B in Rats. Azusa Futatsugi,Yusuke Masuo,Yukio Kato Journal of pharmaceutical sciences 110 5 2274 2021/05
  •  Coculture with hiPS-derived intestinal cells enhanced human hepatocyte functions in a pneumatic-pressure-driven two-organ microphysiological system. Marie Shinohara,Hiroshi Arakawa,Yuuichi Oda,Nobuaki Shiraki,Shinji Sugiura,Takumi Nishiuchi,Taku Satoh,Keita Iino,Sylvia Leo,Yusuke Kato,Karin Araya,Takumi Kawanishi,Tomoki Nakatsuji,Manami Mitsuta,Kosuke Inamura,Tomomi Goto,Kenta Shinha,Wataru Nihei,Kikuo Komori,Masaki Nishikawa,Shoen Kume,Yukio Kato,Toshiyuki Kanamori,Yasuyuki Sakai,Hiroshi Kimura Scientific reports 11 1 5437 2021/03/08
  •  A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models Takeshi Matsumoto,Takashi Komori,Yuta Yoshino,Tadaaki Ioroi,Tsukasa Kitahashi,Hiromu Kitahara,Kohei Ono,Tamami Higuchi,Masayo Sakabe,Hiroshi Kori,Masahiro Kano,Ritsuko Hori,Yukio Kato,Shinji Hagiwara Pharmaceutical Research 38 6 1093 2021/06 
  •  Population Pharmacokinetics of Teicoplanin and Its Dosing Recommendations for Neutropenic Patients With Augmented Renal Clearance for Hematological Malignancies Ken-ichi Sako,Yuta Nakamaru,Kazuro Ikawa,Tomoji Maeda,Sotaro Goto,Yoko Ishihara,Yukio Kato,Yoshikazu Matsuda Therapeutic Drug Monitoring 43 4 519 2021/08 
  •  Multi-omics analysis of hiPSCs-derived HLCs matured on-chip revealed patterns typical of liver regeneration. Mathieu Danoy,Yannick Tauran,Stéphane Poulain,Rachid Jellali,Johanna Bruce,Marjorie Leduc,Morgane Le Gall,Francoise Gilard,Taketomo Kido,Hiroshi Arakawa,Karin Araya,Daiki Mori,Yukio Kato,Hiroyuki Kusuhara,Charles Plessy,Atsushi Miyajima,Yasuyuki Sakai,Eric Leclerc Biotechnology and bioengineering 118 10 3716 2021/01/06
  •  Identification of food-derived isoflavone sulfates as inhibition markers for intestinal breast cancer resistance proteins Agustina R, Masuo Y, Kido Y, Shinoda K, Ishimoto T, Kato Y Drug Metab Dispos 49 11 972 2021
  •  A kinetic-pump integrated microfluidic plate (KIM-Plate) with high usability for cell culture-based multi-organ microphysiological systems Shinha K, Nihei W, Nakamura H, Goto T, Kawanishi T, Ishida N, Yamazaki N, Imakura Y, Mima S, Inamura K, Arakawa H, Nishikawa M, Kato Y, Sakai Y, Kimura H Micromachines 12 9 1007 2021
  •  S-methyl-L-ergothioneine to L-ergothioneine ratio in urine is a marker of cystine lithiasis in a cystinuria mouse model de Heredia ML, Muñoz L, Carru C, Sotgia S, Zinellu A, Serra C, Llebaria A, Kato Y, Nunes V Antioxidant 10 9 1424 2021
  •  Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis Iida N, Yamashita T, Yutani M, Seishima J, Wang Z, Arai K, Okada H, Yamashita T, Sakai Y, Masuo Y, Agustina R, Kato Y, Fujinaga Y, Oshima M, Honda M, Lebreton F, Gilmore MS, Kaneko S Nat Cancer 2 10 1039 2021
  •  Carnitine/organic cation transporter 1 precipitates the progression of interstitial fibrosis through oxidative stress in diabetic nephropathy in mice. Shohei Makiishi,Kengo Furuichi,Yuta Yamamura,Keisuke Sako,Yasuyuki Shinozaki,Tadashi Toyama,Shinji Kitajima,Yasunori Iwata,Norihiko Sakai,Miho Shimizu,Tomoko Hirose-Sugiura,Shuichi Kaneko,Yukio Kato,Takashi Wada Scientific reports 11 1 9093 2021/04/27
  •  Investigation of the hepatic development in the coculture of hiPSCs-derived LSECs and HLCs in a fluidic microenvironment. Mathieu Danoy,Yannick Tauran,Stephane Poulain,Rachid Jellali,Johanna Bruce,Marjorie Leduc,Morgane Le Gall,Yuta Koui,Hiroshi Arakawa,Francoise Gilard,Bertrand Gakiere,Yukio Kato,Charles Plessy,Taketomo Kido,Atsushi Miyajima,Yasuyuki Sakai,Eric Leclerc APL bioengineering 5 2 026104 2021/06
  •  Placental leucine aminopeptidase as a potential specific urine biomarker for invasive ovarian cancer Matsukawa T, Mizutani S, Matsumoto K, Kato Y, Yoshihara M, Shibata K, Kajiyama H  J Clin Med 11 222 2022
  •  Discrimination of hand-foot skin reaction of tyrosine kinase inhibitors based on direct keratinocytes toxicity and vascular endothelial growth factor receptor-2 inhibition Alshammari AH, Masuo Y, Fujita K, Iida N, Shimada K, Wakayama T, Kato Y.  Biochem Pharmacol  197 114914 2022
  •  PHARMACOKINETIC ASPECTS OF PEPTIDE DELIVERY AND TARGETING - IMPORTANCE OF RECEPTOR-MEDIATED ENDOCYTOSIS Y SUGIYAMA,Y KATO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY 20 4 591 1994
  •  Kinetic analysis of receptor-mediated endocytosis (RME) of proteins and peptides: Use of RME as a drug delivery system Y Kato,T Seita,T Kuwabara,Y Sugiyama JOURNAL OF CONTROLLED RELEASE 39 2-3 191 1996/05
  •  Targeted delivery of peptides, proteins, and genes by receptor-mediated endocytosis Y Kato,Y Sugiyama CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS 14 3 287 1997
  •  Toxicological implications of hepatobiliary transporters Y Kato,H Suzuki,Y Sugiyama TOXICOLOGY 181 287 2002/12
  •  Xenobiotic transporter - Adaptor network Yukio Kato DRUG METABOLISM AND PHARMACOKINETICS 22 6 401 2007
  •  Pdz Adaptors: Their Regulation of Epithelial Transporters and Involvement in Human Diseases Tomoko Sugiura,Takuya Shimizu,Ai Kijima,Sosuke Minakata,Yukio Kato JOURNAL OF PHARMACEUTICAL SCIENCES 100 9 3620 2011/09
  •  Critical evaluation and methodological positioning of the transdermal microdialysis technique. A review Franciska Erdo,Naoto Hashimoto,Gellert Karvaly,Noritaka Nakamichi,Yukio Kato JOURNAL OF CONTROLLED RELEASE 233 147 2016/07
  •  Current progress toward a better understanding of drug disposition within the lungs: summary proceedings of the 1st Workshop on Drug Transporters in the Lungs.  Ehrhardt C, Bäckman P, Couet W, Edwards C, Forbes B, Fridén M, Gumbleton M, Hosoya K, Kato Y, Nakanishi T, Takano M, Terasaki T, Yumoto R. J Pharm Sci 106 9 2234-2244 2017
  •  Physiological roles of carnitine/organic cation transporter OCTN1/SLC22A4 in neural cells. Nakamichi N, Kato Y.  Biol Pharm Bull  40 8 1146-1152 2017
  •  Decreased disposition of anticancer drugs predominantly eliminated via the liver in patients with renal failure.  Fujita K, Matsumoto N, Ishida H, Kubota Y, Iwai S, Shibanuma M, Kato Y.  Curr Drug Metab 20 5 361-376 2019
  •  New insights into human endometrial aminopeptidases in both implantation and menstruation. Mizutani S, Matsumoto K, Kato Y, Mizutani E, Mizutani H, Iwase A, Shibata K.  Biochim Biophys Acta 1868 2 140332 2020
  •  Receptor-mediated targeting of peptides and proteins Y Sugiyama,Y Kato ADVANCED BIOMATERIALS IN BIOMEDICAL ENGINEERING AND DRUG DELIVERY SYSTEMS 121 1996
  •  Experimental Approaches to the Study of Drug Transporters Yoshiyuki Kubo,Yukio Kato,Akira Tsuji Drug Transporters: Molecular Characterization and Role in Drug Disposition 533 2006/11/20
  •  Experimental Approaches to the Study of Drug Transporters Yoshiyuki Kubo,Akira Tsuji,Yukio Kato Drug Transporters: Molecular Characterization and Role in Drug Disposition: Second Edition 355 2014/09/02
  •  Regulation of Neurogenesis by Organic Cation Transporters: Potential Therapeutic Implications Takahiro Ishimoto,Yukio Kato Organic Cation Transporters in the Central Nervous System (Part of the Handbook of Experimental Pharmacology book series) 281 2021 
  •  Half-way achievement with "DMPK globalization committee"; what had been and what is to be done for further globalization Kawai Ryosei,Chiba Masato,Hashimoto Yukiya,Hosokawa Masakiyo,Kato Yukio,Nagata Kiyoshi,Tamai Ikumi DRUG METABOLISM AND PHARMACOKINETICS 22 1 1 2007 
  •  New Aspects of Transporter Research: Future may Exist "Beyond the Transport'' Preface Yukio Kato,Ikumi Tamai DRUG METABOLISM AND PHARMACOKINETICS 23 4 221 2008
  •  Overcoming in vitro/in vivo Discrepancies Yukio Kato DRUG METABOLISM AND PHARMACOKINETICS 24 5 409 2009

Conference Presentations

  • Organic cation transporter OCTN1 as possible target for lung pathology.(conference:Workshop on Drug Transporters in the Lungs)(2016/09/22)
  • Role of ABC xenobiotic transporters in drug disposition in the skin.(conference:The Best of the Rest – Drug Transport across Non-traditional Biological Barriers)(2015/10/25)
  • ABC transporters involved in xenobiotics disposition in the skin. (conference:Meet the Experts: Transporter Conference Tokyo 2015)(2015/05/13)
  • Possible roles of xenobiotics transporter OCTN1/SLC22A4 in inflammatory diseases of digestive organs(2014/11/01)

Others

  •  Efforts to overcome in vitro/in vivo discrepancy.  23 4 221-222 2009/10

Arts and Fieldwork

Patent

Theme to the desired joint research

○Transporter-mediated drug uptake and efflux
○Drug metabolism and disposition using gene-knockout animals
○Physiologically-based pharmacokinetic analysis of transporter-mediated drug interaction

Grant-in-Aid for Scientific Research

○「肝障害時における肝細胞増殖因子の体内動態機構の解析」(1994-1994) 
○「肝細胞増殖因子の受容体非介在性消失機構の解析」(1995-1995) 
○「生理活性ペプチド受容体を標的としたドラッグデリバリーシステムの細胞内挙動の制御」(1996-1996) 
○「サイトカインの非線形体内動態機構に基づいた新規デリバリーシステムの開発」(1997-1998) 
○「肝細胞膜に発現するトランスポーターの分子機能におけるシンクロナイゼーション」(1999-2000) 
○「多彩な生物活性を有する肝細胞増殖因子のホメオスタシスに基づいた臓器特異的送達」(1999-2000) 
○「異物排出トランスポーター群の上皮細胞アピカル膜局在を制御する分子シグナル」(2004-2004) 
○「薬物取り込み・排出トランスポーターの細胞膜ソーティングの分子機構と薬理学的意義」(2004-2005) 
○「抗癌剤の消化管毒性回避を目指した小腸上皮細胞取り込み機構の分子論的解析」(2004-2004) 
○「肝腎トランスポーターを介した薬物間相互作用の分子基盤」(2004-2005) 
○「薬物動態制御因子としてのトランスポーターアダプターの役割」(2006-2007) 
○「医薬品の薬効・毒性標的としてのトランスポーター・アダプターネットワーク」(2008-2010) 
○「トランスポートフォトコンバーター:多様な薬の生体膜透過を光に変換する新規計測技術」(2009-2010) 
○「ペプチドトランスポーターを利用した腫瘍細胞トリプルブロック分子標的薬の開発」(2011-2012) 
○「抗酸化物質膜輸送体を標的とした臓器慢性疾患防御の研究と治療への応用」(2012-2015) 
○「ABC膜輸送体を標的とする経皮薬物デリバリーシステムの開発研究」(2013-2014) 

Competitive research funding,Contribution

Collaborative research,Consignment study

Classes (Bachelors)

○Basic Anatomy(2017)
○Seminar in Clinical Pharmacy 2(2017)
○Seminar in Drug Therapeutics(2017)
○Medicinal Chemistry(2017)
○Basic Drug Development(2017)
○Seminar in Pharmaceutical Practice(2017)
○Drug Therapeutics 1(2017)
○Drug Therapeutics 2(2017)
○Introduction to Region-studies(2017)
○Experiments in Pharmaceutical Practice 3(2017)
○World of Coffee(2016)
○Introduction to Region-studies(2016)
○Overseas Active Learning in Pharmaceutical Sciences 1(2016)
○Medicinal Chemistry(2016)
○Laboratory Rotation 2(2016)
○Seminar in Clinical Pharmacy 2(2016)
○Basic Drug Development(2016)
○Experiments in Pharmaceutical Practice 3(2016)
○Seminar in Drug Therapeutics(2016)
○Basic Anatomy(2016)
○Drug Therapeutics 2(2016)
○Drug Therapeutics 1(2016)
○Overseas Active Learning in Pharmaceutical Sciences 2(2016)
○World of Coffee(2016)
○Lecture on Life in Campus and Society(2016)
○Freshman Seminar I(2016)

Classes (Graduate Schools)

○Prediction and Evaluation of Ddrug Efficacy(2017)
○Drug Metabolism(2017)
○Advanced Seminar on Precision Medicine(2017)
○Advanced Course of ADME Studies for Drug Development(2017)
○Pharmaceutical Therapeutics(2017)
○Molecular Pharmaceutics(2017)
○Introduction to Presicion Medicine(2017)
○Pharmaceutical Therapeutics(2016)

International Project

International Students

Lecture themes

Others (Social Activities)

To Page Top